)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals (REGN) investor relations material
Regeneron Pharmaceuticals Leerink Global Healthcare Conference 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Leerink Global Healthcare Conference 2026 summary11 Mar, 2026
Commercial performance and product highlights
EYLEA HD achieved $506 million in Q4, marking 66% year-over-year growth, aided by label enhancements for weekly dosing and RVO indication.
DUPIXENT sales reached $4.9 billion in Q4, up 32% year-over-year, with strong performance across multiple indications and international markets.
Libtayo generated $525 million in Q4, a 13% year-over-year increase, with growth in skin and lung cancer indications and new launches in adjuvant settings.
LYNOZYFIC launch showed positive early uptake in multiple myeloma, with benefits in efficacy, safety, and reduced hospitalizations.
EYLEA HD is positioned as the leading innovative anti-VEGF brand, with expectations for continued growth despite biosimilar competition.
Strategic initiatives and pipeline development
Expansion into new therapeutic areas is supported by a robust commercial infrastructure, enabling launches in neurology and other specialties.
Cemdisiran is expected to launch for generalized myasthenia gravis by early next year, with preparations for a dedicated neurology business unit.
M&A strategy focuses on early-stage and platform opportunities, with commercial synergies not being the primary driver.
The alliance with Sanofi remains central, especially for DUPIXENT, with ongoing discussions about collaboration scope and next-generation assets.
Several ophthalmology pipeline candidates, including programs for uveitis, glaucoma, geographic atrophy, and thyroid eye disease, are advancing toward commercialization.
Market dynamics and forward-looking statements
EYLEA faces ongoing and increasing biosimilar competition, with additional entrants expected in the second half of the year.
EYLEA HD unit growth is projected to be high single digits in Q1, while original EYLEA is expected to continue declining.
The pre-filled syringe for EYLEA HD is important for adoption, with 95% of EYLEA use already via this format.
Fianlimab trial readout is expected in the first half of the year, with study powered to account for potential pembrolizumab outperformance.
Interim analysis for the geographic atrophy program is anticipated toward the end of 2026, focusing on systemic complement inhibition.
EYLEA HD net price outlook Q1
IL-13 long-acting antibody launch timing
Fianlimab trial powering assumptions
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next Regeneron Pharmaceuticals earnings date
Q1 202628 Apr, 2026
Regeneron Pharmaceuticals
Next Regeneron Pharmaceuticals earnings date
Q1 202628 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Regeneron Pharmaceuticals Inc is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company has a pipeline of product candidates comprising multiple therapeutic candidates in Phase I and Phase II clinical studies for the treatment of cancer, wet age-related macular degeneration and diabetic macular edema, atopic dermatitis, asthma, pain, and monoclonal antibodies.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage